Zobrazeno 1 - 10
of 101
pro vyhledávání: '"P. Luigi Zinzani"'
Autor:
Rossana Di Staso, Beatrice Casadei, Frederick L. Locke, Michael Jain, Timothy J. Voorhees, Adam S. Kittai, Mariana Bastos-Oreiro, Antonio Gutiérrez, Alejandro Martin Garcia-Sancho, Maria Jose Terol, Monica Mead, Michael J. Maranzano, Gloria Iacoboni, Pere Barba, Mi Kwon, Rebeca Bailen, Juan Luis Reguera-Ortega, Agrima Mian, Brian Hill, Emmanuel Bachy, Franck Morschhauser, Roch Houot, Catherine Thieblemont, Steven Le Gouill, Riccardo Masetti, Davide Gori, Alessandro Broccoli, Pier Luigi Zinzani, Lisa Argnani
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/43e03c8577e3401699a0eac8f43eb23f
Autor:
Nicole Lamanna, Constantine S. Tam, Jennifer A. Woyach, Alvaro J. Alencar, M. Lia Palomba, Pier Luigi Zinzani, Ian W. Flinn, Bita Fakhri, Jonathon B. Cohen, Arrin Kontos, Heiko Konig, Amy S. Ruppert, Anindya Chatterjee, Richard Sizelove, Livia Compte, Donald E. Tsai, Wojciech Jurczak
Publikováno v:
eJHaem, Vol 5, Iss 5, Pp 929-939 (2024)
Abstract Clinical bleeding events are reported here from 773 patients with B‐cell malignancies receiving pirtobrutinib monotherapy from the phase 1/2 BRUIN study (ClinicalTrials.gov identifier: NCT03740529), either in the presence or absence of ant
Externí odkaz:
https://doaj.org/article/82cd9c8755ab4351873ea8a263b45176
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-11 (2024)
Abstract Follicular lymphoma (FL) is an indolent, germinal center B cell–derived lymphoid neoplasm, for which recent advances in treatment have substantially improved patient survival. However, FL remains an incurable and heterogeneous disease, wit
Externí odkaz:
https://doaj.org/article/85a2892529414ce1aa105915033a0f01
Autor:
Camilla Pellegrini, Francesco Ravaioli, Sara De Fanti, Chiara Pirazzini, Chiara D’Silva, Paolo Garagnani, Claudio Franceschi, Francesca Bonifazi, Pier Luigi Zinzani, Massimiliano Bonafè, Maria Guarino, Raffaele Lodi, Pietro Cortelli, Caterina Tonon, Micaela Mitolo, Luisa Sambati, Luca Morandi, Maria Giulia Bacalini
Publikováno v:
Diagnostics, Vol 14, Iss 22, p 2541 (2024)
Background: Neuronal loss is a major pathological feature of neurodegenerative diseases. The analysis of plasma cell-free DNA (cfDNA) is an emerging approach to track cell death events in a minimally invasive way and from inaccessible areas of the bo
Externí odkaz:
https://doaj.org/article/25944fbd9dd8468983d623d1178b0e57
Autor:
Peter N. Morcos, Jonathan Moss, Rupert Austin, Florian Hiemeyer, Pier Luigi Zinzani, Vita Beckert, Lidia Mongay Soler, Barrett H. Childs, Dirk Garmann
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 11, Pp 1666-1686 (2023)
Abstract Copanlisib dose selection was established under the maximum tolerated dose paradigm, and no dedicated dose‐finding studies have investigated copanlisib dose selection when used in combination with rituximab. In CHRONOS‐3, copanlisib plus
Externí odkaz:
https://doaj.org/article/9de2185aad9e42999937070a78e87dc0
Autor:
Gianmarco Bagnato, Vittorio Stefoni, Alessandro Broccoli, Lisa Argnani, Cinzia Pellegrini, Beatrice Casadei, Francesca Bonifazi, Pier Luigi Zinzani
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 16, Iss 1 (2024)
We report the case of 2 patients with relapsed/refractory peripheral T-cell lymphoma treated with valemetostat tosilate, a selective dual inhibitor of histone-lysine N-methyltransferases enhancer of zeste homolog 1 and 2, and subsequently bridged to
Externí odkaz:
https://doaj.org/article/f3bcfe6454db4c48926e6d674464f884
Autor:
Stefano Pileri, Valentina Tabanelli, Roberto Chiarle, Angelica Calleri, Federica Melle, Giovanna Motta, Maria Rosaria Sapienza, Elena Sabattini, Pier Luigi Zinzani, Enrico Derenzini
Publikováno v:
Hemato, Vol 4, Iss 3, Pp 196-206 (2023)
The concept of gray-zone lymphoma (GZL) has been progressively refined since its introduction in the literature in 1998. For several years, it was applied to a rather broad spectrum of conditions, posing the problem of the differential diagnosis betw
Externí odkaz:
https://doaj.org/article/f8db9eaae74f414eabd0f815345ebeac
Autor:
Howland E. Crosswell, Ann S. LaCasce, Nancy L. Bartlett, David J. Straus, Kerry J. Savage, Pier Luigi Zinzani, Graham P. Collins, Michelle Fanale, Keenan Fenton, Cassie Dong, Harry Miao, Andrew P. Grigg
Publikováno v:
Haematologica, Vol 109, Iss 3 (2023)
Externí odkaz:
https://doaj.org/article/812cd0e47a2943868ab741041339d5d9
Autor:
Farhad Ravandi, Robert J. Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C. Barrientos, Seema A. Bhat, James S. Blachly, Alessandro Broccoli, Timothy Call, Dai Chihara, Claire Dearden, Judit Demeter, Sasha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E. Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B. Johnston, Jeffrey Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A. Parikh, Jae H. Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A. Rogers, Alan Saven, John F. Seymour, Tamar Tadmor, Martin S. Tallman, Constantine S. Tam, Philip A. Thompson, Xavier Troussard, Clive S. Zent, Thorsten Zenz, Pier Luigi Zinzani, Bernhard Wörmann, Kanti Rai, Michael Grever
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 12, Pp 1-7 (2022)
Abstract A significant body of literature has been generated related to the detection of measurable residual disease (MRD) at the time of achieving complete remission (CR) in patients with hairy cell leukemia (HCL). However, due to the indolent natur
Externí odkaz:
https://doaj.org/article/b522c851a9074f98bd78424982d9e633
Autor:
Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, Kirit M. Ardeshna, Mehdi Hamadani, Brian Hess, Brad S. Kahl, John Radford, Melhem Solh, Anastasios Stathis, Pier Luigi Zinzani, Ying Wang, Yajuan Qin, Luqiang Wang, Zhiying Cindy Xu, Carmelo Carlo-Stella
Publikováno v:
Haematologica, Vol 109, Iss 4 (2023)
Therapies that demonstrate durable, long-term responses with manageable safety and tolerability are needed for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]),
Externí odkaz:
https://doaj.org/article/bd44e81cc44e4e969307a93b7e55be0c